Wyeth and Santaris Pharma have entered into a worldwide strategic alliance to discover, develop and commercialize new medicines based on Santaris’ Locked Nucleic Acid (LNA) drug platform, which allows specific targeting and regulation of microRNAs (miRNAs) and messenger RNAs (mRNAs) as a means to affect gene expression mediated by the targeted RNAs. Santaris will receive an upfront payment of $7 million in cash and Wyeth will make a $10 million equity investment in the company. Santaris...